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Abstract The aim of this study was to assess the effects of
replacement with recombinant human growth hormone
(rhGH) in patients with GH deﬁciency (GHD) after treat-
ment of acromegaly. Intervention study. Sixteen patients (8
men, age 56 years), treated for acromegaly by surgery and
radiotherapy, with an insufﬁcient GH response to insulin-
induced hypoglycaemia, were treated with 1 year of rhGH
replacement. Study parameters were assessed at baseline
and after 1 year of rhGH replacement. Study parameters
were cardiac function, body composition, bone mineral
density (BMD), fasting lipids, glucose, bone turnover
markers, and Quality of Life (QoL). During rhGH replace-
ment IGF-I concentrations increased from -0.4 ± 0.7 to
1.0 ± 1.5 SD (P = 0.001), with a mean daily dose of
0.2 ± 0.1 mg in men and 0.3 ± 0.2 mg in women. None-
theless, rhGH replacement did not alter cardiac function,
lipid and glucose concentrations, body composition or QoL.
Bone turnover markers (PINP and b crosslaps) levels
increased (P = 0.005 and P = 0.021, respectively), paral-
leled by a small, but signiﬁcant decrease in BMD of the hip.
The beneﬁcial effects of rhGH replacement in patients with
GHD during cure from acromegaly are limited in this study.
Keywords Growth hormone deﬁciency  
Growth hormone replacement   Acromegaly
Introduction
Growth hormone deﬁciency (GHD) in adults is character-
ized by an adverse cardiovascular metabolic proﬁle, altered
body composition (reﬂected in reduced muscle strength
and mass, and visceral obesity), decreased bone mass,
decreased cardiac function and decreased quality of life
(reviewed in [1]). Treatment with recombinant human
growth hormone (rhGH) ameliorates symptoms and signs
of the GHD syndrome in the short [2] and in the long-term
[3, 4]. GHD is a well-known sequel of pituitary radio-
therapy, e.g. for non-functioning adenomas, adrenocorti-
cotrope hormone- or prolactin-secreting adenomas [5].
Remarkably, GHD can also be induced by treatment of
active acromegaly. We have documented a diminished GH
increase to insulin-induced hypoglycemia during long-term
follow-up in 36% of the patients with acromegaly after
postsurgical radiotherapy [6].
Almost all randomized controlled studies on the efﬁcacy
of rhGH replacement in adult GHD have excluded patients
previously treated for acromegaly. Nonetheless, two inter-
vention studies have reported on the effects of rhGH
replacement in patients with GHD after previous treatment
ofacromegaly.Inasubanalysisofacromegalicpatientswith
GHD extracted from the large KIMS database, 6 months of
rhGHreplacementhadnosigniﬁcantbeneﬁcialeffectsinthe
acromegalic patients [7]. In addition, a recent study com-
pared the effects of 2 years of rhGH replacement on body
composition, muscle strength, bone mass and metabolic
parameters between ten patients previously treated for
acromegaly and ten patients treated for non-functioning
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had decreased muscle endurance and increased LDL con-
centrations compared to the other patients, but after 2 years
of rhGH replacement there were no differences between
both groups [8].
The aim of this study was to evaluate 1 year of rhGH
replacement on heart function, quality of life, glucose and
lipid metabolism, body composition and bone mass and
turnover in order to extend the exploration whether GH
replacement is beneﬁcial in acromegalic patients with
GHD during long-term biochemical cure.
Patients and methods
Patients
We enrolled 16 acromegalic patients (8 men and 8
women), who developed GHD after combined pituitary
surgery and radiotherapy in the study. Inclusion criteria
were previous treatment for acromegaly by surgery and/or
radiotherapy and an insufﬁcient GH increase to insulin-
induced hypoglycemia (short-acting insulin 0.05–0.1 U/kg
body weight, blood samples drawn at 0, 20, 30, 45, 60 and
90 min; nadir glucose levels below 2.2 mmol/l) [9]. The
increase in GH concentrations was considered insufﬁcient,
when the peak GH response was below 3 lg/l [10].
Fifteen patients had been treated with primary surgery
and secondary conventional radiotherapy mean interval
after radiotherapy 18 years (range 4–29 years). The other
patient was diagnosed with pituitary apoplexy of a GH
producing adenoma. Because GH concentrations remained
elevated, he underwent surgery and subsequently devel-
oped complete anterior pituitary failure. Clinical details
were published previously [11].
Additional hormone replacement therapy was kept sta-
ble for at least 3 months prior to study inclusion, and was
only adjusted thereafter when necessary. The purpose,
nature, and possible risks of the study were explained to all
subjects and written informed consent was obtained. The
study protocol was approved by the ethics committee of the
Leiden University Medical Center.
Study design
Study parameters were assessed both at baseline and after
1 year of rhGH replacement. The following variables were
measured: fasting concentrations of lipoproteins, glucose,
and IGF-I, body composition, bone turnover markers
and bone mass, echocardiography, and Quality of Life
parameters.
Growth hormone vials of 1 ml were manufactured
and provided by Novo Nordisk Pharma, Denmark. Growth
hormone replacement dose was started at 0.2 mg/day and,
subsequently, titrated in the ﬁrst 12 weeks of the study to
obtain an IGF-I concentration within the age- and gender-
adjusted reference range, according to Growth Hormone
Research Society guidelines [10].
The mean age of the patients was 56 years (range
34–75 years). The interval between radiotherapy and the
start of the study was 18 years (range 4–29 years). TSH
deﬁciency was present in ﬁve patients, ACTH deﬁciency in
nine patients, and LH-FSH deﬁciency in eight patients (see
Table 1).
Body composition
Body weight and height, waist circumference, hip cir-
cumference, systolic and diastolic blood pressure (SBP and
DBP, respectively) were measured. Waist-hip (WH) ratio
was calculated. Body weight was measured to the nearest
0.1 kg, and body height was measured barefoot to the
nearest 0.001 m. Lean body mass and fat mass were
measured with DXA (Hologic 4500; Hologic Inc., Wal-
tham, MA, USA).
Markers for bone turnover and bone mass
The following serum markers of bone turnover were
measured: N-terminal propeptides of type I collagen
(PINP), as a marker for bone synthesis, and b-crosslaps as a
marker for bone resorption. Bone mineral density (BMD)
was measured by DXA (Hologic 4500; Hologic Inc.,
Waltham, MA, USA). Sites measured were the lumbar
Table 1 Clinical characteristics of the 16 patients with growth hor-
mone deﬁciency after acromegaly
Age (year) Gender Substitution therapy
65 Male None
65 Male None
59 Male Thyroxine, Testosterone, Hydrocortisone
75 Female Hydrocortisone
66 Female None
62 Female Hydrocortisone
66 Female Thyroxine, Estradiol, Hydrocortisone
40 Female Thyroxine, Estradiol, Hydrocortisone
43 Male Testosterone
56 Male Thyroxine, Testosterone, Hydrocortisone
48 Male Thyroxine, Testosterone, Hydrocortisone
51 Female None
34 Female Hydrocortisone
74 Male Testosterone
45 Male Testosterone
50 Female Hydrocortisone
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123spine (L1-L4) and the femoral neck (left and right). Mean
BMD of the left and right femoral neck was calculated.
Mean T and Z scores were calculated for total left and right
hip using the NHANES reference values. The CV of BMD
measurements was 1% and the machine was cross-cali-
brated at regular interval.
Echocardiography
Echocardiography was performed while the patients were
in the left lateral decubitus position using a commercially
available system (Vingmed Vivid-7, General Electric-
Vingmed, Milwaukee, WI, USA). Standard parasternal
(long- and short-axis) and apical views (2-, and 4-, and
long-axis) were obtained. M-mode images were obtained
from the parasternal long-axis views for quantitative
assessment of LV dimensions (inter-ventricular septum
thickness (IVST), posterior wall thickness (PWT), LV end-
diastolic diameter (LVEDD), LV end-systolic diameter
(LVESD), fractional shortening (FS) and LV ejection
fraction (LVEF)) [12].
The following parameters of diastolic function were
obtained: diastolic transmitral peak velocities (E and A
wave) and the E/A ratio. Quantitative diastolic data were
derived from tissue Doppler imaging (TDI). For TDI anal-
ysis, the digital cine loops were analyzed using commercial
software (Echopac 6.1; General Electric-Vingmed). The
sample volume (4 mm
2) was placed in the LV basal portion
of the septum (using the 4-chamber views). The following
parameters (mean values calculated from three consecutive
heartbeats) were derived: early diastolic velocity (E0), late
diastolic velocity (A0) and the E0/A0 ratio. The severity of
valvular regurgitation was assessed by two independent
expert readers blinded to the clinical data on a qualitative
scale of trace, mild, moderate, or severe, using previously
described methods [13, 14]. Left ventricular mass (LVM)
was calculated by the cube formula, and using the correc-
tion formula proposed by Devereux et al. [15]: 0.8 9
{1.04 [(LVEDD ? PWT ? IVST)
3 - LVEDD
3]} ? 0.6.
The data were assessed by two independent observers,
blinded for the clinical data of the patients.
Quality of life
Quality of life was assessed using four different validated
health-related quality of life questionnaires
Hospital anxiety and depression scale (HADS): The HADS
consists of 14 items pertaining to anxiety and depression.
Each item is measured on a 4-point scale. Scores for the
anxiety and depression subscale range from 0 to 21 and for
the total score from 0 to 42. A high score points to more
severe anxiety and depression [16].
Multidimensional fatigue index (MFI-20): The MFI-20
contains 20 statements to assess fatigue [17]. Five different
dimensions of fatigue (four items each) are calculated from
these statements; (1) general fatigue; (2) physical fatigue;
(3) reduced activity; (4) reduced motivation and (5) mental
fatigue. Every statement is measured on a 5-point scale;
scores vary from 0 to 20. Higher scores indicate higher
experienced fatigue.
Nottingham health proﬁle (NHP): The NHP is fre-
quently used in patients with pituitary disease to assess
general well-being and QoL. The survey consists of 38 yes/
no questions, which are subdivided in 6 scales assessing
impairments, i.e. pain (8 items), energy level (3 items),
sleep (5 items), emotional reactions (9 items), social iso-
lation (5 items) and disability/functioning, i.e. physical
mobility (8 items) [18, 19]. Subscale scores are calculated
as a weighted mean of the associated items and are
expressed as a value between 0 and 100. The total score is
the mean of the six subscales.
Quality of life-assessment of growth hormone deﬁciency
in adults (QoL-AGDHA): This disease speciﬁc quality of
life questionnaire has been developed speciﬁcally for the
detection of deﬁcits in needs achievements in areas which
have shown to be commonly affected in adults with GHD
[20]. The questionnaire comprises 25 items, which are
summed to form a total score. Higher numerical scores (to
a maximum of 25) denote poorer quality of life.
Assays and dynamic tests
Growth hormone reserve was evaluated by the insulin
tolerance test in fasting conditions (short-acting insulin
0.05–0.1 U/kg body weight, blood samples drawn at 0, 20,
30, 45, 60 and 90 min; the nadir glucose concentration
should drop below 2.2 mmol/l) [9]. The increase in GH
concentration was considered insufﬁcient, when the peak
GH concentration was below 3 lg/l [10].
Serum IGF-I concentration was measured with the Im-
mulite 2500 system (Diagnostic Products Corporation, Los
Angeles, USA). The intra-assay variation was 5.0 and 7.5%
at mean serum levels of 8and 75 nmol/l,respectively. IGF-I
levels are expressed as standard deviation-scores (SDS),
using lambda-mu-sigma (LMS) smoothed reference curves
based on measurements in 906 healthy individuals [21, 22].
IGFBP-3 was measured using an immunometric tech-
nique on an IMMULITE Analyzer (Diagnostic Products
Corporation, Los Angeles, USA). The lower limit of
detection was 0.02 mg/l and inter-assay variation was 4.4
and 4.8% at 0.91 and 8.83 mg/l. A Hitachi P800 auto
analyzer (Roche, Mannheim, Germany) was used to
quantify serum concentrations of glucose, total cholesterol
and TG. HDL was measured with a homogenous enzymatic
assay (Hitachi 911, Roche, Mannheim, Germany). LDL
Pituitary (2009) 12:339–346 341
123cholesterol concentrations (LDL) were calculated using the
Friedewald formula. C-crosslinking terminal telopeptide of
type I collagen (b-crosslaps) and procollagen type I ami-
noterminal propeptide (PINP) by chemoluminescence
immunoassay with the Modular Analytics E-170 system
(Roche Diagnostics, Almere, The Netherlands).
Statistics
Statistical analysis was performed using SPSS for Win-
dows, version 14.0 (SPSS Inc. Chicago, Illinois, USA).
Results are scored as the mean ± standard deviation (SD),
unless speciﬁed otherwise. The data were analyzed with the
paired samples Student’s t-test. Statistical signiﬁcance was
set at P\0.05.
Results
IGF-1 and IGFBP-3 concentrations
One year of rhGH replacement increased IGF-I SD scores
and IGF-BP3 levels (baseline IGF-I SD score: -0.4 ± 1.7
and 1.0 ± 1.5 at 1 year, P\0.001; baseline IGFBP-3:
4.2 ± 1.2 mg/l and 5.2 ± 1.4 mg/l after 1 year, P\0.001).
Cardiovascular risk parameters and body composition
During rhGH replacement lipid proﬁles did not change. In
addition, blood pressure (systolic and diastolic) and fasting
glucose concentrations did not change (Table 2). Mean
lean body mass increased by almost 4 kg and total fat mass
decreased by approximately 3 kg, but these differences did
not reach statistical signiﬁcance.
Bone parameters
RhGH replacement increased plasma concentrations of
bone turnover markers (PINP and b-crosslaps) in all
patients (Table 3; Fig. 1). During rhGH replacement bone
mass at the lumbar spine remained unchanged in all
patients, but decreased signiﬁcantly at the femoral neck by
4% (Table 3; Fig. 1).
Cardiac parameters and quality of life parameters
During rhGH replacement there were no signiﬁcant chan-
ges in cardiac parameters or QoL parameters (Tables 4, 5).
Discussion
In this prospective study, we evaluated the effect of rhGH
treatment on a range of relevant parameters in GHD
patients, previously treated for acromegaly. During rhGH
replacement IGF-I concentrations increased into the
Table 2 Metabolic and antroprometric parameters before and after
1 year of rhGH replacement
Before After P-value
Total cholesterol (mmol/l) 6.0 ± 1.0 5.7 ± 1.2 0.317
TG (mmol/l) 1.8 ± 1.0 2.1 ± 1.3 0.222
HDL-cholesterol (mmol/l) 1.4 ± 0.5 1.4 ± 0.4 0.597
LDL-cholesterol (mmol/l) 4.1 ± 0.8 3.9 ± 1.0 0.250
Glucose (mmol/l) 4.6 ± 0.6 4.7 ± 0.5 0.138
SBP (mm Hg) 138 ± 17 135 ± 10 0.222
DBP (mm Hg) 87 ± 98 8 ± 8 0.924
Waist circumference (cm) 102.8 ± 11.4 103.6 ± 12.5 0.599
WH ratio 0.9 ± 0.1 0.9 ± 0.1 0.921
LBM (kg) 57.1 ± 13.0 61.7 ± 13.4 0.102
Fat mass (kg) 34.8 ± 16.0 31.3 ± 14.7 0.367
TG triglycerides; HDL high-density lipoprotein; LDL low-density
lipoprotein; SBP systolic blood pressure; DBP diastolic blood pres-
sure; WH ratio waist-to-hip ratio; LBM lean body mass
Table 3 Bone markers and biochemical parameters of bone turnover
before and after 1 year rhGH replacement
Before After P-value
PINP (ng/ml) 29.1 ± 19.5 44.3 ± 33.4 0.005
b crosslaps (ng/ml) 0.2 ± 0.1 0.3 ± 0.2 0.021
BMD lumbar spine (g/cm
2) 1.1 ± 0.2 1.1 ± 0.2 0.640
BMD femoral neck (g/cm
2) 0.85 ± 0.17 0.81 ± 0.15 \0.001
T score total hip -0.30 ± 1.5 -0.24 ± 1.4 0.434
Z score total hip 0.26 ± 1.6 0.37 ± 1.5 0.125
PINP N-terminal propeptides of type I collagen; BMD bone mineral
density
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Fig. 1 Bone mineral density decreased in all patients during 1 year
rhGH replacement (n = 16, P\0.001)
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123age- and gender-adjusted normal range, but neither cardiac
parameters, nor any of the cardiovascular risk parameters
or quality of life parameters changed during rhGH treat-
ment. Bone turnover markers increased during rhGH
replacement, which was associated with a decrease of bone
mineral density at the femoral neck of 4%, whereas the
bone mass of the lumbar spine remained unchanged. These
data indicate that the effects of rhGH treatment of GHD
patients previously treated for acromegaly are limited.
Data on the manifestations of GHD after treatment for
acromegaly are limited. Two previous studies reported
several clinical manifestations in this particular patient
group [7, 8]. The ﬁrst study compared patients with GHD
after treatment for acromegaly and Cushing’s disease with
patients with GHD due to other etiologies [7]. No differ-
ences in body mass index, waist-hip ratio, serum lipid
concentrations, bone mineral density (at the lumbar spine
and femoral neck), or IGF-I SD score were found in
patients with GHD after acromegaly compared with
patients with GHD due to other etiologies [7]. In the second
study, muscle strength, bone mass and metabolic indices
were compared between ten patients previously treated for
acromegaly and ten patients treated for non-functioning
pituitary disease [8]. Although there were no differences
between both groups after 2 years of rhGH replacement, at
baseline, patients with acromegaly had a decreased muscle
endurance and increased LDL concentrations compared to
the other patients, which points towards differences in their
response to the treatment [8]. However, body fat decreased
and lean body mass increased in that study in the patients
with non-functioning pituitary disease, whereas it did not
change in the same number of patients with GHD after
acromegaly simultaneously studied [8], in agreement with
our ﬁndings.
In adult patients with GHD, rhGH replacement increases
bone mineral density [23], left ventricular mass and stroke
volume [24], lean body mass [1], and quality of life [25],
whereas it improves the serum lipid proﬁle [26]. These
effects are apparent within 6–12 months and are maintained
during continued treatment with rhGH in the long-term [4,
24, 26–29]. However, it appears that these abnormalities
associated with GHD in adults are not always reversed
completely solely by rhGH replacement [29, 30] and that
some patients might beneﬁt more from combined treatment
of rhGH with, for instance, lipid-lowering agents and bis-
fosfonates [31, 32].
Table 4 Cardiac parameters before and after 1 year rhGH
replacement
Before After P-value
LVEDD (mm) 51.6 ± 5.8 47.0 ± 15.5 0.165
LVESD (mm) 34.3 ± 4.4 32.6 ± 7.5 0.222
IVST (mm) 12.2 ± 3.4 12.4 ± 3.9 0.704
PWT (mm) 10.2 ± 1.6 10.0 ± 1.3 0.594
FS (%) 35.1 ± 6.7 37.0 ± 6.1 0.319
LVEF (%) 63.5 ± 8.4 66.3 ± 7.5 0.244
E (mm/s) 0.5 ± 0.2 0.5 ± 0.1 0.745
A (mm/s) 0.6 ± 0.2 0.6 ± 0.1 0.789
E/A ratio 1.0 ± 0.3 0.9 ± 0.3 0.589
E0 (cm/s) 0.6 ± 0.2 0.5 ± 0.3 0.629
A0 (cm/s) 0.7 ± 0.1 0.6 ± 0.4 0.300
E0/A0 ratio 0.8 ± 0.4 0.9 ± 0.3 0.589
LVM (g) 233 ± 64 215 ± 105 0.307
LVEDD left ventricular end-diastolic diameter; LVESD left ventric-
ular end-systolic diameter; FS fractional shortening; LVEF left ven-
tricular ejection fraction; IVST inter-ventricular septum thickness;
PWT posterior wall thickness; LVM left-ventricular mass
Table 5 Quality of life
parameters at baseline and after
1 year rhGH replacement in
patients with GHD after
previous treatment for
acromegaly
HADS, NHP, MFI-20, QoL-
AGDHA higher scores: more
impairment
Before After P-value
QoL NHP Energy 55.2 ± 38.2 41.8 ± 35.4 0.125
Pain 19.4 ± 21.8 14.1 ± 18.8 0.278
Emotional reaction 12.0 ± 16.4 13.2 ± 20.0 0.603
Sleep 13.6 ± 26.9 14.1 ± 24.4 0.913
Physical mobility 20.1 ± 20.8 16.0 ± 23.7 0.258
Social isolation 12.0 ± 17.1 10.6 ± 17.1 0.586
QoL MFI-20 General fatigue 15.4 ± 4.5 14.2 ± 4.7 0.154
Physical fatigue 12.9 ± 5.2 13.2 ± 5.2 0.747
Reduction in activity 11.4 ± 4.9 11.8 ± 4.9 0.625
Reduction in motivation 10.8 ± 4.4 10.1 ± 4.5 0.415
Mental fatigue 9.3 ± 4.6 9.8 ± 4.3 0.650
QoL HADS Anxiety 4.6 ± 2.4 4.9 ± 2.3 0.453
Depression 6.0 ± 4.4 6.1 ± 4.3 0.933
Total score 10.6 ± 5.0 11.0 ± 5.3 0.674
QoL-AGDHA 7.6 ± 6.1 7.7 ± 5.9 0.880
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123In our study, parameters of both bone resorption and
bone formation increased, paralleled by a net decrease in
bone mineral density at the femoral neck, in agreement
with the observed increase in bone turnover found during
2 years of rhGH replacement in these patients by Norrman
et al. [8]. In this latter study, however, no treatment dif-
ferences in the response of bone mineral density between
patients previously treated for acromegaly and patients
previously treated for non-functioning pituitary disease
were found [8]. It is important to note, however, that there
are several small differences with our study. The patients in
the study of Norrman et al. were included between 1991
and 1997. Hence, the initial dose previously applied before
the consensus statement of the Growth Hormone Research
Society in 1998 was ﬁrst based on weight in some patients,
but was subsequently gradually lowered when the weight
based dose regime was abandoned. In addition, almost all
patients studied (90%) were female [8]. These differences
could explain the discrepant effects of rhGH replacement
found on bone mineral density between the present study
and the study by Norrman et al. [8].
The decrease in BMD found in our study could point
towards a different response to rhGH replacement in
patients previously exposed to persistently increased GH
concentrations. Alternatively, this observation may indi-
cate that the possible beneﬁcial effect of rhGH replace-
ment on bone in these patients is insufﬁcient to
compensate the ongoing bone loss after previous GH
excess in these speciﬁc patients. In active acromegaly,
bone mineral density is increased [33] and this favorable
effect seems to persist after successful biochemical cure
[34]. However, in patients with biochemical cure of
acromegaly, radiotherapy was an independent negative
predictor of bone mineral density at the femoral neck [34].
Almost all patients in our cohort had been treated previ-
ously by radiotherapy. On the other hand, in patients with
adult-onset GHD due to other etiologies, some, but not all,
studies have found a decreased bone mass at the lumbar
spine (reviewed in [1]). Replacement with rhGH in those
patients seems to modestly increase bone mineral density
after 1 year [27]. However, the lack of the increase in
BMD, usually seen during rhGH replacement but absent in
our speciﬁc patients, is in accordance with the only other
study performed in patients with GHD after treatment of
acromegaly [7]. Further longer-term studies are needed to
clarify this issue.
Body composition did not change during rhGH
replacement, whereas it has been consistently found to be
altered by rhGH replacement in patients with GHD due to
other diseases (an increase in lean body mass and a
decrease in body fat [1]). However, the trends seen in our
study point towards similar changes in body composition in
patients previously treated for acromegaly. Interestingly,
body fat decreased and lean body mass increased in the
study of Norrman et al. [8] in the patients with non-func-
tioning pituitary disease, whereas it did not change in the
same number of patients with GHD after acromegaly
simultaneously studied. Replacement with rhGH did not
improve QoL parameters. Various aspects of QoL seem to
improve slightly during rhGH replacement in adults with
GHD due to other diseases [25]. Therefore, it is likely that
other factors in our patients with GHD after treatment for
acromegaly explain the lack of effect on QoL during rhGH
replacement, such as persisting joint related complaints
[35] and/or unfavorable late effects of previous radiother-
apy [36].
Considering the beneﬁcial effects of rhGH replacement
in patients with GHD due to other causes than acromegaly,
substitution in this particular subgroup is warranted. We
did not ﬁnd many marked beneﬁcial effects of rhGH
replacement in these patients. Higher, non-physiological,
doses of rhGH could possibly result in detectable changes
in the targeted parameters, as has been extensively docu-
mented in patients with GHD not pre-exposed to acro-
megaly. In clinical practice, however, current treatment
guidelines from the Growth Hormone Research Society,
advocate to titrate rhGH dose to target IGF-I concentra-
tions within the normal age-related reference range, to
ensure a therapeutic dose also in those patients with severe
GHD, and avoid side effects of rhGH replacement.
In conclusion, the effects of rhGH replacement in
patients with GHD after treatment for acromegaly seem to
be limited. The observed effect on bone resorption and in
bone mineral density might be affected by ongoing bone
loss despite rhGH replacement seen in acromegaly after
radiotherapy, or by the response to rhGH of bone after
previous long-term exposure to GH excess. Larger long-
term studies in this speciﬁc patient group are warranted to
clarify the issue whether the effects of rhGH replacement
in GHD might be altered by previous acromegaly. How-
ever, these patients will most probably become increas-
ingly rare since the introduction of effective drug treatment
for acromegaly.
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